Citations

Clear

6055 citation(s) found for "Vu, Peter".

Escalation of Oxygenation Modalities and Mortality in Critically Ill Immunocompromised Patient With Acute Hypoxemic Respiratory Failure: A Clustering Analysis of a Prospectively Multicenter, Multinational Dataset
Yvin, Élise, Kouatchet, Achille, Mokart, Djamel, Martín‐Loeches, Ignacio , Seguin, Amélie, Louw, Andry van de, Mabrouki, Asma, Bredin, Swann, Klouche, Kada , Mehta, Sangeeta , Bruneel, Fabrice , Lisboa, Tiago, Viana, William, Pickkers, Peter , Russell, Lene , Rusínová, Kateřina , Rello, Jordi, Clère-Jehl, Raphaël , Lafarge, Antoine , Lemiale, Virginie , Mercat, Alain , Russell, Lene , Martin-Loeches, Ignacio , Kouatchet, Achille, Mokart, Djamel , Taccone, Fabio Silvio , Pène, Frédéric , Bauer, Philippe R. , Seguin, Amélie, Metaxa, Victoria , Montini, Luca , Lisboa, Tiago, Rello, Jordi , Barbier, Francois, Azoulay, Élie , Darmon, Michaël

Mayo Clinic

Critical Care Medicine | February 27, 2025 | Volume: 53 | Issue: 5 | Pages: e1055-e1065

10.1097/ccm.0000000000006600 | PMID 40013850 Get It

OBJECTIVES: Acute hypoxemic respiratory failure in immunocompromised patients remains the leading cause of admission to the ICU, with high case fatality. The response to the initial oxygenation strategy may be predictive of outcome. This study aims to assess the response to the evolutionary profiles of oxygenation strategy and the association with survival. DESIGN: Post hoc analysis of EFRAIM study with a nonparametric longitudinal clustering technique (longitudinal K-mean). SETTING AND PATIENTS: Multinational, observational prospective cohort study performed in critically ill immunocompromised patients admitted for an acute respiratory failure. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 1547 patients who did not require invasive mechanical ventilation (iMV) at ICU admission were included. Change in ventilatory support was assessed and three clusters of change in oxygenation modality over time were identified. Cluster A: 12.3% iMV requirement and high survival rate, n = 717 patients (46.3%); cluster B: 32.9% need for iMV, 97% ICU mortality, n = 499 patients (32.3%); and cluster C: 37.5% need for iMV, 0.3% ICU mortality, n = 331 patients (21.4%). These clusters demonstrated a high discrimination. After adjustment for confounders, clusters B and C were independently associated with need for iMV (odds ratio [OR], 9.87; 95% CI, 7.26–13.50 and OR, 19.8; 95% CI, 13.7–29.1). CONCLUSIONS: This study identified three distinct highly performing clusters of response to initial oxygenation strategy, which reliably predicted the need for iMV requirement and hospital mortality.
Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Collin, Lindsay J. , Cushing‐Haugen, Kara L. , Terry, Kathryn L. , Goode, Ellen L. , Wu, Anna H. , Harris, Holly R. , Sasamoto, Naoko , Cramer, Daniel W. , Modugno, Francesmary , Elishaev, Esther , Moysich, Kirsten B. , Fasching, Peter A. , Pearce, Celeste Leigh , Menon, Usha , Gayther, Simon A. , Wentzensen, Nicolas , Goodman, Marc T. , George, Joshy , Talhouk, Aline , Anglesio, Michael S. , Ramus, Susan J. , Bowtell, David D.L. , Tworoger, Shelley S. , Schildkraut, Joellen M. , George, Joshy , Fu, Zhuxuan , Moysich, Kirsten , Fasching, Peter A , Pearce, Celeste Leigh , Menon, Usha , Gentry‐Maharaj, Aleksandra , Gayther, Simon A , Wentzensen, Nicolas , Goodman, Marc T , George, Joshy , Talhouk, Aline , Anglesio, Michael S , Ramus, Susan J , Bowtell, David D , Tworoger, Shelley S , Schildkraut, Joellen M , Webb, Penelope M , Doherty, Jennifer A , Cramer, Daniel W , Modugno, Francesmary , Harris, Holly R , Elishaev, Esther , Cushing-Haugen, Kara L , Fu, Zhuxuan , Webb, Penelope M. , Doherty, Jennifer A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 26, 2025 | Volume: 34 | Issue: 5 | Pages: 762-773

10.1158/1055-9965.epi-24-1143 | PMID 40009771 Get It

Abstract Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of HGSC. We investigated associations between different epidemiologic risk factors and HGSC molecular subtypes. Methods: We pooled data from 11 case–control studies with epidemiologic and tumor gene expression data from custom NanoString CodeSets developed through a collaboration within the Ovarian Tumor Tissue Analysis consortium. The PrOTYPE-validated NanoString-based 55-gene classifier was used to assign HGSC gene expression subtypes. We examined associations between epidemiologic factors and HGSC subtypes in 2,070 cases and 16,633 controls using multivariable-adjusted polytomous regression models. Results: Among the 2,070 HGSC cases, 556 (27%) were classified as C1.MES, 340 (16%) as C5.PRO, 538 (26%) as C2.IMM, and 636 (31%) as C4.DIF. The key factors, including oral contraceptive use, parity, breastfeeding, and family history of ovarian cancer, were similarly associated with all subtypes. Heterogeneity was observed for several factors. Former smoking [OR = 1.25; 95% confidence interval (CI) = 1.03, 1.51] and genital powder use (OR = 1.42; 95% CI = 1.08, 1.86) were uniquely associated with C2.IMM. History of endometriosis was associated with C5.PRO (OR = 1.46; 95% CI = 0.98, 2.16) and C4.DIF (OR = 1.27; 95% CI = 0.94, 1.71) only. Family history of breast cancer (OR = 1.44; 95% CI = 1.16, 1.78) and current smoking (OR = 1.40; 95% CI = 1.11, 1.76) were associated with C4.DIF only. Conclusions: This study observed heterogeneous associations of epidemiologic and modifiable factors with HGSC molecular subtypes. Impact: The different patterns of associations may provide key information about the etiology of the four subtypes.
Society of Anesthesia and Sleep Medicine Opinion Paper: High-Flow Nasal Oxygen Therapy for Early Postoperative Management of Patients With Sleep-Disordered Breathing
Pappu, Ameya , Auckley, Dennis , Cloward, Tom V., Dominguez, Jennifer E. , Dupuy-McCauley, Kara , Gali, Bhargavi , Gay, Peter C. , Hillman, David R. , McConville, Sarah S., Nafiu, Olubukola O. , Won, Christine , Gay, Peter, Singh, Mandeep

Mayo Clinic

Anesthesia & Analgesia | February 25, 2025 | Volume: 141 | Issue: 4 | Pages: 740-747

10.1213/ane.0000000000007424 | PMID 39998995 Get It

Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status
Lambertini, Matteo , Blondeaux, Eva , Tomasello, Loredana Maria, Agostinetto, Elisa , Hamy, Anne‐Sophie , Kim, Hee Jeong , Franzoi, Maria Alice , Bernstein‐Molho, Rinat , Hilbers, Florentine , Pogoda, Katarzyna , Bajpai, Jyoti , Phillips, Kelly‐Anne , Rousset‐Jablonski, Christine , Renaud, Tiphaine , Cui, Wanyuan , Wong, Stephanie M. , Ruddy, Kathryn J. , Marchis, Laura De , Wildiers, Hans , Bajpai, Jyoti , Ignatiadis, Michail , Moore, Halle C F , Partridge, Ann H , Phillips, Kelly-Anne , Toss, Angela , Rousset-Jablonski, Christine , Criscitiello, Carmen , Ferrari, Alberta , Fruscio, Robert , Cui, Wanda , Wong, Stephanie M , Vernieri, Claudio , Ruddy, Kathryn J , Dieci, Maria Vittoria , Matikas, Alexios , Rozenblit, Mariya , Villarreal-Garza, Cynthia , De Marchis, Laura , Puglisi, Fabio , Rodriguez-Wallberg, Kenny A , Livraghi, Luca , Bruzzone, Marco , Boni, Luca , Balmaña, Judith , Lambertini, Matteo , Hamy, Anne-Sophie , Pogoda, K. , Wildiers, Hans , Ignatiadis, Michail , Moore, Halle C. F. , Partridge, Ann H. , Paluch–Shimon, Shani , Fruscio, Robert , Dieci, Maria Vittoria , Villarreal‐Garza, Cynthia , Duhoux, François P. , Livraghi, Luca , Bruzzone, Marco , Balmañà, Judith

Mayo Clinic

Journal of Clinical Oncology | February 24, 2025 | Volume: 43 | Issue: 14 | Pages: 1706-1719

10.1200/jco-24-01334 | PMID 39993249 Get It

PURPOSE To investigate the clinical behavior of breast cancer in young BRCA carriers according to the specific BRCA gene ( BRCA1 v BRCA2 ) and the association of the timing of genetic testing (before v at diagnosis) with prognosis. METHODS This was an international, multicenter, hospital-based, retrospective cohort study that included 4,752 patients harboring germline pathogenic/likely pathogenic variants (PVs) in BRCA1 or BRCA2 , who were diagnosed with stage I-III invasive breast cancer at 40 years or younger between January 2000 and December 2020 in 78 centers worldwide (ClinicalTrials.gov identifier: NCT03673306 ). RESULTS Compared with BRCA2 carriers (n = 1,683), BRCA1 carriers (n = 3,069) had more frequently hormone receptor–negative (74.4% v 15.5%) and high-grade (77.5% v 49.1%) tumors. Similar outcomes were observed in BRCA1 and BRCA2 carriers but with a different pattern and risk of disease-free survival events over time. Compared with patients tested for BRCA at diagnosis (ie, between 2 months before and up to 6 months after diagnosis; n = 1,671), those tested before diagnosis (ie, any time up to 2 months before diagnosis; n = 411) had smaller tumors (T1: 61.3% v 32.4%), less nodal involvement (N0: 65.9% v 50.8%), less frequently received chemotherapy (84.4% v 92.9%), and axillary dissection (37.5% v 47.4%). Patients tested before diagnosis had better overall survival (OS; unadjusted hazard ratio [HR], 0.61 [95% CI, 0.40 to 0.92]); however, this result lost statistical significance after adjustment for potential confounders including tumor stage (adjusted HR, 0.74 [95% CI, 0.47 to 1.15]). CONCLUSION This global study provides evidence on the different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers. Identifying a BRCA PV in healthy individuals was associated with earlier-stage breast cancer diagnosis and lower treatment burden, as well as better unadjusted OS.
Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition
Fiorica, Peter N. , Golmard, Lisa , Kim, Jung , Bao, Riyue , Lin, Frank Y. , Roy, Angshumoy , Pribnow, Allison , Perrino, Melissa R. , Masliah‐Planchon, Julien , Michalak-Provost, Sophie , Wong, Jennifer , Filser, Mathilde , Bourdeaut, Franck , Brahimi, Afane, Ingster, Olivier, Jackson, Sarah A. , Sasaki, Mark M. , Fowler, Trent, Ng, Anita , Corbett, Ryan J. , Kaufman, Rebecca , Haley, Jeremy S. , Carey, David J. , Huang, Kuan‐lin , Diskin, Sharon J. , Al‐Kateb, Hussam , Schultz, Kris Ann P. , Onel, Kenan , Stoppa-Lyonnet, Dominique , Bourdeaut, Franck , Brahimi, Afane , Ingster, Olivier , Saulnier Sholler, Giselle , Jackson, Sarah A , Sasaki, Mark M , Fowler, Trent , Ng, Anita , Corbett, Ryan J , Kaufman, Rebecca S , Haley, Jeremy S , Carey, David J , Huang, Kuan-Lin , Diskin, Sharon J , Rokita, Jo Lynne , Al-Kateb, Hussam , McGee, Rose B , Schiffman, Joshua D , Chen, Kenneth S , Stewart, Douglas R , Parsons, D Williams , Plon, Sharon E. , Schultz, Kris Ann P , Onel, Kenan , Perrino, Melissa R , Lin, Frank Y , Stoppa‐Lyonnet, Dominique , Rokita, Jo Lynne , Chen, Kenneth , Parsons, D. Williams

Mayo Clinic

Clinical Cancer Research | February 24, 2025 | Volume: 31 | Issue: 8 | Pages: 1491-1503

10.1158/1078-0432.ccr-24-2785 | PMID 39992227 Get It

Abstract Purpose: DROSHA, DGCR8, and DICER1 regulate miRNA biogenesis and are commonly mutated in cancer. Although DGCR8 and DICER1 germline pathogenic variants (GPV) cause autosomal dominant tumor predisposition, no association between DROSHA GPVs and clinical phenotypes has been reported. Experimental Design: After obtaining informed consent, sequencing was performed on germline and tumor samples from all patients. The occurrence of germline DROSHA GPVs was investigated in large pediatric and adult cancer datasets. The population prevalence of DROSHA GPVs was investigated in the UK Biobank and Geisinger DiscovEHR cohorts. Results: We describe nine children from eight families with heterozygous DROSHA GPVs and a diagnosis of pineoblastoma (n = 8) or Wilms tumor (n = 1). A somatic second hit in DROSHA was detected in all eight tumors analyzed. All pineoblastoma tumors analyzed were classified as miRNA processing–altered 1 subtype. We estimate the population prevalence of germline DROSHA loss-of-function variants to be 1:3,875 to 1:4,843 but find no evidence for increased adult cancer risk. Conclusions: This is the first report of DROSHA-related tumor predisposition. As pineoblastoma and Wilms tumor are also associated with DICER1 GPVs, our results suggest that the tissues of origin for these tumors are uniquely tolerant of general miRNA loss. The miRNA processing–altered 1 pineoblastoma subtype is associated with older age of diagnosis and better outcomes than other subtypes, suggesting DROSHA GPV status may have important clinical and prognostic significance. We suggest that genetic testing for DROSHA GPVs be considered for patients with pineoblastoma, Wilms tumor, or other DICER1-/DGCR8-related conditions and propose surveillance recommendations through research studies for individuals with DROSHA GPVs.
Left Ventricular Entry to Reduce Brain Lesions During Catheter Ablation: A Randomized Trial
Marcus, Gregory M. , Tung, Roderick , Gerstenfeld, Edward P. , Hue, Trisha F. , Lin, Feng , Cheng, Jing , Weiss, J. Peter , Tzou, Wendy S. , Hsia, Henry H. , Ehdaie, Ashkan , Cooper, Daniel H. , Bunch, T. Jared , Arkles, Jeffrey , Lee, Adam , Hadjis, Alexios , Nguyen, Duy T. , Chelu, Mihail G. , Valderrábano, Miguel , Bhave, Prashant D. , Beaser, Andrew D. , Kanagasundram, Arvindh N. , Wazni, Oussama M. , Bradfield, Jason S. , Wall, Grace, Chang, Kathleen , Yang, Michelle, Montenegro, Gabrielle, Jarrott, Sabrina, Kramer, Joel H. , Kim, Anthony , Morris, Yonca, Dillon, W.P. , Hsia, Henry , Nazer, Babak , Lee, Adam , Hadjis, Alexios , Chelu, Mihail G , Hsu, Jonathan C , Valderrábano, Miguel , Bhave, Prashant D , Beaser, Andrew D , Kanagasundram, Arvindh , Wazni, Oussama , Chang, Kathleen , Jarrott, Sabrina , Kim, Anthony S , Dillon, William P , Tzou, Wendy , Weiss, Peter J , Marcus, Gregory M , Moss, Joshua D. , Hsu, Jonathan C. , Montenegro, Gabrielle C , Morris, Yvonne M.

Mayo Clinic

Circulation | February 24, 2025 | Volume: 151 | Issue: 15 | Pages: 1051-1059

10.1161/circulationaha.124.071352 | PMID 39989365 Get It

BACKGROUND: Catheter ablation of ventricular arrhythmias, one of the most rapidly growing procedures in cardiac electrophysiology, is associated with magnetic resonance imaging–detected brain lesions in more than half of cases. Although a retrograde aortic approach is conventional, modern tools enable entry through a transseptal approach that may avoid embolization of debris from the arterial system. We sought to test the hypothesis that a transseptal puncture would mitigate brain injury compared with a retrograde aortic approach. METHODS: The TRAVERSE trial (Transseptal Versus Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli) was a multicenter randomized controlled comparative effectiveness trial. Patients with left ventricular arrhythmias undergoing catheter ablation procedures were randomly assigned to a transseptal puncture approach compared (1:1) with a retrograde aortic approach. The primary outcome was the presence of an acute brain lesion detected by magnetic resonance imaging. Secondary outcomes included clinically manifest complications, procedural efficacy, and 6-month neurocognitive assessments. RESULTS: Among the 62 patients randomly assigned to a retrograde aortic approach with postoperative brain magnetic resonance imaging, 28 (45%) exhibited an acute brain lesion compared with 19 of the 69 (28%) of those randomized to a transseptal puncture ( P =0.036). No differences in clinically manifest complications or procedural efficacy were observed. More patients in the retrograde aortic arm were categorized as having a high likelihood of cognitive impairment at 6 months (33% compared with 19% of those in the transseptal arm), but substantial loss to follow-up was present. CONCLUSIONS: Among patients undergoing left ventricular catheter ablation procedures, a transseptal approach reduced the risk of acute brain lesions by nearly half compared with a retrograde aortic approach without sacrificing safety or efficacy. Given a likely embolic pathogenesis, the brain magnetic resonance imaging findings may reflect a propensity to other organ damage; these findings may extend to other procedures requiring left ventricular entry. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03946072.
Primary Fixation and Cyclic Performance of Posterior Horn Medial Meniscus Root Repair With Knotless Adjustable Suture Anchor–Based Fixation: A Human Biomechanical Evaluation Over 100,000 Loading Cycles
Bachmaier, Samuel , Krych, Aaron J. , Smith, Patrick A. , Nuelle, Clayton W. , Müller, Peter E., Bedi, Asheesh , Krych, Aaron J , Wijdicks, Coen A.

Mayo Clinic

The American Journal of Sports Medicine | February 19, 2025 | Volume: 53 | Issue: 5 | Pages: 1093-1100

10.1177/03635465251317210 | PMID 39972533 Get It

Background: Recent biomechanical evidence for adjustable suture anchor (ASA)–based posterior medial meniscus root (PMMR) fixation has shown promising results compared with conventional transtibial pull-out repair (TPOR). However, ASA fixation has not been evaluated in human tissue to 100,000 cycles. Hypothesis: ASA repair would lead to increased primary fixation strength and less cyclic displacement than conventional TPORs. Study Design: Controlled laboratory study. Methods: A total of 32 human medial menisci were used, 8 of which were intact specimens and served as native controls. For the others, PMMR tears were created and repaired using 3 different techniques (n = 8 group). Two conventional PMMR repairs were prepared consisting of two No. 2 simple sutures (TSS) and two No. 2 sutures in a Mason-Allen (MA) configuration, all tied over a cortical button. The knotless ASA repair was fixed in MA with repair sutures tensioned at 120 N (MA-120). The repairs’ initial force, stiffness, and relief displacement from the tensioned state toward repair unloading (2 N) were measured after fixation. All repair constructs were loaded for 100,000 cycles, with displacement and stiffness measured, and finally were pulled to failure. Results: The TPORs demonstrated similar primary fixation and cyclic loading behavior except for initial cyclic displacement (cycle 10). The ASA repair provided a higher initial repair load ( P < .001) and stiffness ( P < .001) with relief displacement similar to conventional TPORs. Lower initial cyclic displacement ( P < .011; cycle 10) with overall higher repair stiffness ( P < .011) resulted in significantly lower displacement ( P < .001) throughout testing for ASA repair. Although both TPORs were completely loose after 100,000 cycles, the ASA repair achieved near-native dynamic meniscal stabilization. The TSS repair had lower overall ultimate load ( P < .001) and ultimate stiffness ( P < .023) compared with the ASA repair. All repairs had lower ultimate stiffness and loads than the native meniscus ( P < .001). Conclusion: The ASA repair resulted in improved primary PMMR fixation that was stiffer with less cyclic displacement than conventional TPORs and approached that of the human meniscal function after 100,000 load cycles in a cadaveric model. However, all repair techniques had lower ultimate strength than the native human PMMR. Clinical Relevance: Knotless ASA meniscus root fixation resulted in higher tissue compression and less displacement in a cadaveric model; however, future clinical series with surveillance imaging will define the overall significance of healing rates.
Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer
Raja, Remya , Mangalaparthi, Kiran K. , Madugundu, Anil K. , Jessen, Erik , Pathangey, Latha , Magtibay, Paul M. , Butler, Kristina , Christie, Elizabeth L. , Pandey, Akhilesh , Curtis, Marion , Christie, Elizabeth L , Pandey, Akhilesh , Pandey, Akhilesh , Curtis, Marion

Mayo Clinic

Science Advances | February 19, 2025 | Volume: 11 | Issue: 8 | Pages: No page available

10.1126/sciadv.ads7405 | PMID 39970218 Get It

Increased infiltration of CD3 + and CD8 + T cells into ovarian cancer (OC) is linked to better prognosis, but the specific antigens involved are unclear. Recent reports suggest that HLA class I can present peptides from noncoding genomic regions, known as noncanonical or cryptic peptides, but their immunogenicity is underexplored. To address this, we used immunopeptidomic analysis and RNA sequencing on five metastatic OC samples, which identified 311 cryptic peptides (40 to 83 per patient). Despite comprising less than 1% of total peptides, cryptic peptides from noncoding transcripts emerged as the predominant antigen class when compared to the other major classes of known tumor-specific and tumor-associated antigens in OC samples. Notably, nearly 70% of the prioritized cryptic peptides elicited T cell activation, as evidenced by increased 4-1BB and IFN-γ expression in autologous CD8 + T cells. This study reveals noncoding cryptic peptides as an important class of immunogenic antigens in OC.
Artificial Intelligence ECG Diastolic Dysfunction and Survival in Cardiac Intensive Care Unit Patients
Jentzer, Jacob C. , Lee, Eunjung , Attia, Zachi I. , Kane, Garvan C. , López-Jiménez, Francisco , Noseworthy, Peter A. , Friedman, Paul A. , Oh, Jae K. , Attia, Zachi I , Hillerson, Dustin , Lopez-Jimenez, Francisco , Noseworthy, Peter A , Friedman, Paul A , Oh, Jae K. , Jentzer, Jacob C

Mayo Clinic

Journal of the American Heart Association | February 19, 2025 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/jaha.124.037839 | PMID 39968804 Get It

Background Left ventricular diastolic dysfunction (LVDD) predicts mortality in patients in cardiac intensive care units. An artificial intelligence enhanced ECG (AIECG) algorithm can predict LVDD and mortality in general populations but has not been examined in cardiac intensive care units. Methods This historical cohort study included consecutive adults admitted to Mayo Clinic cardiac intensive care unit from 2007 to 2018 with an admission AIECG. The AIECG assigned the LVDD grade (0–3). Medial mitral E/e' ratio >15 on transthoracic echocardiogram (TTE) defined elevated filling pressures. In‐hospital and 1‐year mortality was evaluated, before and after multivariable adjustment. Results We included 11 868 patients (median age 69.5 years, 37.7% female); 48% had heart failure and 44% had acute coronary syndromes. AIECG LVDD grade was 0 (normal), 33%; 1, 7%; 2, 39%; and 3, 21%. In‐hospital and 1‐year mortality increased in each higher AIECG LVDD grade. After adjustment, each higher AIECG LVDD grade was associated with higher in‐hospital (adjusted odds ratio [OR], 1.22 [95% CI, 1.13–1.32]) and 1‐year mortality (adjusted hazard ratio [HR], 1.23 [95% CI, 1.19–1.29]); this persisted after adjustment for TTE measurements. Patients with grade 2 or 3 LVDD by AIECG and medial mitral E/e' ratio >15 by TTE had the highest in‐hospital (adjusted OR, 2.54 [95% CI, 1.69–3.88]) and 1‐year (adjusted HR, 2.03 [95% CI, 1.65–2.48]) mortality, whereas patients meeting either of these criteria had similar, elevated mortality. Conclusions The AIECG LVDD grade was strongly associated with in‐hospital and 1‐year mortality in patients in cardiac intensive care units, even after adjusting for clinical variables and TTE measurements. Patients with concordant AIECG and TTE for elevated filling pressures were at highest risk.
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Hansen, Doris K. , Peres, Lauren C. , Dima, Danai , Richards, Alicia, Shune, Leyla , Afrough, Aimaz , Midha, Shonali , Dhakal, Binod , Kocoglu, Mehmet H. , Atrash, Shebli , Ferreri, Christopher, Davis, James A. , Bhurtel, Jenny , Wagner, Charlotte B , Bansal, Radhika , Smith, Kinaya, Avila, Gabriel De, Purvey, Sneha , Hosoya, Hitomi , Mikkilineni, Lekha , Oswald, Laura B. , Gaballa, Mahmoud , Forsberg, Peter A. , Janakiram, Murali , Htut, Myo , Maringanti, Sireesha Asoori, Kalariya, Nilesh, Hashmi, Hamza , Sborov, Douglas W. , Khouri, Jack , Raza, Shahzad , Atanackovic, Djordje , Alsina, Melissa , Freeman, Ciara Louise , Voorhees, Peter M. , Anderson, Larry D. , Martin, Thomas, Patel, Krina K. , Sidana, Surbhi , Castaneda Puglianini, Omar , Davis, James A , Bhurtel, Evguenia , McGuirk, Joseph , Wagner, Charlotte , Bansal, Radhika , Lieberman-Cribbin, Alex , De Avila, Gabriel , Purvey, Sneha , Hosoya, Hitomi , Kaur, Gurbakhash , Herr, Megan M. , Janakiram, Murali , Reshef, Ran , Sborov, Douglas W , Anwer, Faiz , Khouri, Jack , Alsina, Melissa , Locke, Frederick L , Voorhees, Peter , Anderson, Larry D , Lin, Yi , Patel, Krina , Sidana, Surbhi , Dima, Danai , Kocoglu, Mehmet H , Raza, Shahzad , Atrash, Shebli , Hansen, Doris K , Dhakal, Binod , Puglianini, Omar Castañeda , McGuirk, Joseph P. , Costello, Patrick , Kaur, Gurbakhash , Pasvolsky, Oren , Reshef, Ran , Nadeem, Omar , Anwer, Faiz , Locke, Frederick L. , Richard, Shambavi , Lin, Yi

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 13 | Pages: 1597-1609

10.1200/jco-24-01730 | PMID 39965175 Get It

PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, and survival among patients with RRMM treated with standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of patients with RRMM leukapheresed by December 31, 2022, with the intent to receive SOC ide-cel or cilta-cel at 19 institutions. An inverse probability of treatment weighting (IPTW) approach was used to compare outcomes by therapy type. RESULTS A total of 641 patients were leukapheresed by December 31, 2022, with ide-cel (n = 386) and cilta-cel (n = 255). Five hundred eighty-six patients were infused (n = 350 for ide-cel; n = 236 for cilta-cel) with a median follow-up of 12.6 and 13.0 months for ide-cel and cilta-cel, respectively. After IPTW, patient characteristics were well balanced. Cilta-cel was associated with higher likelihood of grade ≥3 cytokine release syndrome (CRS; odds ratio [OR], 6.80 [95% CI, 2.28 to 20.33]), infections (OR, 2.03 [95% CI, 1.41 to 2.92]), second primary malignancies (OR, 1.77 [95% CI, 0.89 to 3.56]), and delayed neurotoxicity (OR, 20.07 [95% CI, 4.46 to 90.20]). Cilta-cel was also associated with better treatment responses (≥complete response: OR, 2.42 [95% CI, 1.63 to 3.60]), longer progression-free survival (hazard ratio [HR], 0.48 [95% CI, 0.36 to 0.63]), and longer overall survival (HR, 0.67 [95% CI, 0.46 to 0.97]). No associations were observed between therapy type and immune effector cell–associated neurotoxicity syndrome, any CRS, severe cytopenia at days 30 and 90, or nonrelapse mortality. We observed consistent findings when repeating the analyses restricting the ide-cel cohort to patients infused during the same time period as Food and Drug Administration approval for cilta-cel (≥March 2022). CONCLUSION Cilta-cel demonstrated superior efficacy and survival, with higher incidence of certain toxicities, compared with ide-cel.